Physician profile

Cecil T Holbert

Family Medicine · Philippi, WV

NPI 1003803891

$10,780.96

in general payments reported to CMS, 2019-2025

42 companies · $1,506 in 2025

The $1,506 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,558.04
Education$79.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,592.35 2019-2025 Airsupra, Farxiga, Breztri
Abbvie INC. $1,520.48 2019-2025
Novo Nordisk INC $1,473.07 2019-2025 Rybelsus, Ozempic, Wegovy
Pfizer INC. $1,166.57 2019-2025
Astellas Pharma US INC $659.25 2019-2025 Veozah, Myrbetriq
Janssen Pharmaceuticals, INC $315.58 2020-2024 Spravato
Amgen INC. $310.17 2019-2025 Evenity
Bayer Healthcare Pharmaceuticals INC. $299.45 2022-2025
Exact Sciences Corporation $273.41 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Novartis Pharmaceuticals Corporation $260.07 2019-2024
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $244.42 2020-2025 Xifaxan
Boehringer Ingelheim Pharmaceuticals, INC. $244.18 2019-2024 Tradjenta, Jardiance
Lilly USA, LLC $241.76 2019-2025 Zepbound, Mounjaro, Trulicity
Sunovion Pharmaceuticals INC. $220.25 2019-2021
Sanofi-Aventis U.S. LLC $214.81 2019-2022
Show all 42 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $214.10 2022-2024 Eliquis
Merck Sharp & Dohme LLC $203.76 2019-2023 Verquvo, Belsomra, Steglatro
Glaxosmithkline, LLC. $185.42 2019-2023 Trelegy Ellipta, Shingrix, Bexsero
Abbott Laboratories $148.56 2021-2023 Freestyle Libre 2
Xeris Pharmaceuticals, INC. $141.66 2022-2023 Gvoke Hypopen
Biohaven Pharmaceutical Holding Company LTD. $126.61 2022
Takeda Pharmaceuticals U.S.A., INC. $105.71 2019-2023 Trintellix
Vanda Pharmaceuticals INC. $71.40 2021-2022
Corcept Therapeutics $44.36 2019-2024 Korlym
Shire North American Group INC $43.28 2019
Verona Pharma, INC. $43.17 2025 Ohtuvayre
Phathom Pharmaceuticals, INC. $43.08 2025 Voquezna
Mylan Specialty L.P. $37.17 2019-2024 Yupelri
Nestle Healthcare Nutrition INC. $35.98 2022
Daiichi Sankyo INC. $34.93 2021
Melinta Therapeutics, LLC $32.94 2019
Ultragenyx Pharmaceutical INC. $32.05 2019-2022
Sanofi Pasteur INC. $31.90 2020-2023
Allergan, INC. $28.77 2020-2022
Amarin Pharma, INC. $25.78 2019-2020
Alkermes, INC. $22.04 2023 Aristada, Lybalvi
Genentech USA, INC. $19.64 2020
Insulet Corporation $17.39 2024 Omnipod
Viatris Specialty LLC $16.91 2025 Yupelri
Shield Therapeutics INC $15.11 2024
Supernus Pharmaceuticals, INC. $11.88 2022
Biohaven Pharmaceuticals, INC. $11.54 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cecil T Holbert

$10,780.96

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $1,506 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/90669/cecil-t-holbert

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.